The classification of breast tumors continues to evolve, with new knowledge from research being applied in practice. The new volume of the World Health Organization (WHO) Classification from 2019 is an update of the fourth edition of breast tumors, published in 2012. The descriptions of breast diseases follow the familiar systematic approach of previous volumes. The content is organized in the following sequence: from benign epithelial proliferations and precursors, through benign neoplasms, to in situ and invasive breast cancer, followed by fibroepithelial and nipple tumors, mesenchymal and hematolymphoid neoplasms, tumors of the male breast and genetic tumor syndromes. A brief introduction precedes the contents of each chapter of the book to provide an overview of the nosological units involved and to highlight key changes in the current classification. New histological variants of mammary carcinoma have been introduced, others have completely disappeared, some of them have been moved to another category of tumors, and still others have been transformed from a special subtype carcinoma into a growth pattern of invasive breast carcinoma of no special type. Neuroendocrine tumors are consistent with the same tumors located in other organs and systems, and the criteria for both microinvasion and mixed forms of breast cancer are indicated.
The classification of breast tumors is a dynamic process that uses many sources of up-to-date information that have emerged since the publication of the latest WHO update. Some of the innovations could be integrated very successfully into the algorithms of digital pathology, which would improve the diagnostic accuracy and thus would lead to optimization of the choice of therapeutic strategies and estimation of the correct prognosis.
Baslaim MM, Junainah EM, Ahmad HH, Semilan AF, Al-Ghamdi AO, Rahimuddin NO, et al. Glycogen Rich Clear Cell Carcinoma (GRCC) of the breast may not have a poor prognosis. Int J Surg Case Rep. 2017;33:92–96.
Kini H, Bhat S, Suresh PK, Thomas M. Clear cell carcinoma of breast lipid-rich variant. J Can Res Ther. 2019;15:1167-1169.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. World Health Organization classification of tumours of the breast. 4th ed. Lyon: IARC Press;2012.
Lillemoe TJ, Michaela L, Tsai ML, Swenson KK, Susnik B, Krueger J, et al. Clinicopathologic analysis of a large series of microinvasive breast cancers. Breast J. 2018;24(4):574–579.
Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 2018;31(12):1770–1786.
Tan PH, Schnitt SJ, van de Vijver MJ, Ellis IO, Lakhani SR. Papillary and neuroendocrine breast lesions: the WHO stance. Histopathology. 2015;66(6):761–770.
Tominaga J, Hama H, Kimura N, Takahashi S. MR imaging of medullary carcinoma of the breast. European Journal of Radiology 2009;70:525–529.
World Health Organization Classification of Tumours Editorial Board. Breast tumours. 5th ed. Lyon: International Agency for Research on Cancer;2019.
